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Aim: The objective of our review is to investigate the association between dermatomyositis
patients and nasopharyngeal carcinoma (NPC) together with the clinical presentation of the
patients and their management in otorhinolaryngology.
Background: NPC is a malignant disease with good prognosis on early diagnosis. However,
the relationship between the dermatomyositis and NPC and its management is not well
deﬁned.
Materials and methods: A 10-year retrospective review of case records of 21 dermatomyositis
patients seen in Otorhinolaryngology Department of Hospital Selayang from January 2000
to  November 2010.
Results: These patients ranged from 19 to 74 years old and a total of 8 (38%) out of 21 adults
with dermatomyositis were detected to have malignancy. Five out of 8 patients had NPCParaneoplastic (62.5%). The mean age of patients with NPC and dermatomyositis was 48 years. NPC is
diagnosed in 4 out of 5 patients (80%) in the ﬁrst year of diagnosis of dermatomyositis. The
clinical ﬁndings of the examination of nasopharynx ranged from hyperemia to exophytic
nasopharyngeal mass. Histologically, it is only related to NPC of WHO  types II and III.
Conclusions: There is a strong relationship between dermatomyositis and malignancy,
especially NPC. Clinicians should have a high index of suspicion for malignancy in all
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dermatomyositis patients. Rigid nasoendoscopies and biopsies, serum Epstein–Barr viral
capsid IgA antibody and imaging studies are helpful in detecting NPC in dermatomyositis
patients.
©  2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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D.  Background
ermatomyositis is deﬁned as an idiopathic inﬂam-
atory myopathy with clinically distinctive cutaneous
anifestations.1 However, when the symptoms are associated
ith malignancies, the condition is known as paraneoplastic
yndrome which represents the clinical manifestation of the
emote and indirect effects produced by tumor metabolites
r other products.2
Dermatomyositis is highly associated with various types
f malignancies, namely carcinoma of nasopharynx, breast,
ung, colorectal, uterus and non-Hodgkin lymphoma.3
0–47% of dermatomyositis patients have an underlying
alignancy.4–6 Out of these, nasopharyngeal carcinoma (NPC)
ad been reported as the most common type of cancer related
o dermatomyositis in Asia3,4,7 where NPC is found in more
han 40% of the total cases of malignancies in dermato-
yositis patients.3,4,7,8 The onset of NPC in dermatomyositis
atients is usually within the ﬁrst 5 years from the diagnosis
f dermatomyositis.5
.  Aim
he objective of our review is to investigate the association
etween dermatomyositis patients and nasopharyngeal car-
inoma (NPC) together with the clinical presentation of the
atients and their management in otorhinolaryngology.
.  Materials  and  methods
n this 10-year retrospective study, the case records of 21
atients who were diagnosed with dermatomyositis from
anuary 2000 until November 2010 were reviewed using the
ospital’s electronic medical records. All of the patients were
onﬁrmed to have dermatomyositis by physicians based on
he clinical features and investigations including muscle
iopsy.
The criteria for diagnosis of dermatomyositis were based
n Tanimoto’s classiﬁcation and diagnostic criteria for
olymyositis and dermatomyositis.9 Skin lesions include
eliotrope rash, Gottron’s sign and erythema or purpura
n extensor surfaces of the extremity joints.9 The items
ncluded in the criteria were proximal muscle weakness, mus-
le grasping and spontaneous pain, non-destructive arthritis
r arthralgia, elevated creatinine kinase or adolase, pres-
nce of systemic inﬂammatory signs, myogenic changes on
lectromyography, positive anti Jo-1 antibody and patho-
ogic ﬁndings compatible with inﬂammatory myositis.9
ermatomyositis were diagnosed if patients had at least oneout of three skin lesions and four out of eight other criteria
items.9
Patients diagnosed to have dermatomyositis were referred
to the otorhinolaryngology department for head and neck
examination and diagnostic work up to detect head and neck
malignancy.
The diagnostic work out includes thorough history tak-
ing, general examination of the ear, nose and throat followed
by ﬂexible nasopharyngolaryngoscopy and biopsy of the post
nasal space of any suspicious lesion supplemented by ﬁne
needle aspiration of any cervical lymph node.
All patients who had no detectable head and neck malig-
nancy were reviewed again by the otorhinolaryngologist
particularly if the work up for any malignancy was nega-
tive and the dermatomyositis symptoms frequently relapsed,
or for those who showed no improvement despite being on
immunosuppressive treatment.
4.  Results
A total of 21 dermatomyositis patients were reviewed from
January 2001 until November 2010. There were 10 male (48%)
patients and 11 female (52%) patients. The youngest patient
was 19 years old and the oldest patient was 74 years old. The
mean age of presentation was 43.8 years old. Eight of the der-
matomyositis patients were below 40 years old (38%) and the
remaining 13 were above 40 years old (62%).
Eight out of 21 patients (38%) were detected to have malig-
nancies (breast, nasopharynx and lymphoma) and 5 out of the
8 (62.5%) had NPC. Among those who were diagnosed to have
NPC, the male to female ratio was 4:1.
The mean age of the NPC patients with dermatomyositis
was 55.2 years (range 39–74 years). The maximum age inci-
dence was in the ﬁfth decade. In our center, 8 dermatomyositis
patients were below 40 years old (3 males and 5 females) and
only 1 (12.5%) was related to malignancy (NPC).
Meanwhile, 7 out of 13 patients (54%) aged 40 years and
above had a malignancy. There were 7 males and 6 females in
this group. Out of these 7 who had a malignancy, 4 patients
(31%) had NPC (1 female and 3 males), 2 patients had breast
carcinoma and 1 had lymphoma (Fig. 1).
There were a total of 5 patients with nasopharyngeal car-
cinoma. Three were detected concurrently with the diagnosis
of dermatomyositis while the other 2 patients were diagnosed
during subsequent follow ups which ranged from 2 months to
38 months. Thus, the diagnosis of NPC was made in as many
as 80% of the patients within the ﬁrst year of the diagnosis of
dermatomyositis (3 concurrently and 1 after 2 months during
follow up). The ﬁfth patient was diagnosed 4 years from onset
of dermatomyositis. One of them presented with epistaxis and
otitis media and another with a submandibular mass. It is
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Fig. 1 – This bar graft shows the number of
dermatomyositis patients with malignancies,
dermatomyositis patients with nasopharyngeal carcinoma
and the total number of dermatomyositis patients
in the second year and another within the third year fromaccording to gender.
important to note that the rest of patients did not show any
clinical symptoms related to NPC during their ﬁrst presenta-
tion.
All patients with suspicious lesions, even without promi-
nent masses (hyperemic area, fullness, hypertrophy, asymme-
try of nasopharyngeal wall), were biopsied and three out of
ﬁve biopsies were noted to be positive for malignancy. The
nasopharyngeal masses of 3 patients were biopsied and two
were squamous cell carcinoma, while the third one showed
normal lymphoid tissue (adenoid).
One of the patients who were diagnosed concurrently with
dermatomyositis had a stage T4 NPC (involving cavernous
sinus). It was conﬁrmed after a biopsy was done as the nasoen-
doscopy examinations showed only hyperemia of the fossa
of Rosenmuller. Two patients had normal nasopharynx dur-
ing their ﬁrst visit but subsequently fullness of the fossa
of Rosenmuller was noted in one of them, while the other
developed a mass. The fourth patient had a mass at the
nasopharynx during the ﬁrst visit and the ﬁfth presented
with a slight fullness but no mass over the fossa of Rosen-
muller. A total of 3 patients were diagnosed at stage 1 (all
3 were T1N0), one at stage 2 (T2N2) and another at stage
4(T4N0).
Three out of the 5 (60%) dermatomyositis patients with NPC
had non-keratinizing differentiated squamous cell carcinoma
of the nasopharynx (WHO type II). The remaining 40% (2 out of
5 patients) had non-keratinizing undifferentiated squamous
cell carcinoma of the nasopharynx (WHO type III).
5.  Discussion
Dermatomyositis is a paraneoplastic syndrome and it is
strongly associated with different types of malignancy. The
association between the myopathy with malignancy was ﬁrst
reported by Stertz10 in 1916 and many  centers have since
reported the association of dermatomyositis and malignancy.
In Malaysia, Tang and Thevarajah3 reported in 2010 that 47.4%
of dermatomyositis patients had underlying malignancy.
Chan7 reviewed the records of Singaporean dermatomyositisiotherapy 1 9 ( 2 0 1 4 ) 332–336
patients and noted that 41% of dermatomyositis patients had
cancer. While in Taiwan, a cohort study done in 2010 reported
that 9.4% of dermatomyositis patients had cancer.5 In our
study, 38% of the dermatomyositis patients in the present
series had cancer, and this shows that the incidence of cancer
in dermatomyositis patients in the South East Asia region is
high.
Dermatomyositis is not cancer speciﬁc. Instead, it is asso-
ciated with different types of cancer in different populations.
In Asia, it is strongly associated with NPC. A study done in
Singapore showed that NPC was the most common cancer
associated with dermatomyositis (46.7%).7,11 In Malaysia, a
previous study done in 2010 showed similar ﬁgures (61.1%)3
as in our study (62.5%). A study done in Guandong, China,
also showed that NPC was the main type of cancer associated
with dermatomyositis (51.3%).4 However, the risk of develop-
ing a speciﬁc type of cancer associated with dermatomyositis
is unequal in different populations. Hill et al.12 reported on
speciﬁc cancer types in dermatomyositis in Sweden, Denmark
and Finland, where ovarian, lung and pancreatic cancers were
reported as the three main types of cancers associated with
dermatomyositis.12 In Scotland, lung cancer was the most
common cancer related to dermatomyositis,6 while in Tunisia
it was breast cancer.13
The risk of malignancy is higher in patients with aged 40
and above. In our center, only 13.0% of those below 40 years
old suffered from NPC, while 31% of our patients aged 40 years
and above had NPC. Zhang et al.4 also reported that the risk
of dermatomyositis patients developing cancer was higher in
the older age group (7.4% in patients below 40 years old and
24.4% in patients aged 40 years and above). Stockton et al.6 also
reported a higher risk of malignancy seen in dermatomyositis
patients aged between 45 and 75 years.
Male patients had stronger malignancy association com-
pared to female patients in our population. Forty percent of
males and 9.1% of females were diagnosed to have NPC. It
was also shown in a study in China where men  were more
likely to have malignancy4 than women (35.0% versus 17.0%),
while in Singapore, it was noted that the female to male ratio
of dermatomyositis (without malignancy) was 2.53:1 but the
ratio was reversed when malignancy was associated with the
female to male ratio which was 1:3.11 However, reports from
other centers showed inconsistent results with regards to gen-
der predilection. In the United States,1 Tunisia13 and Europe14
where NPC is less common, women are more  likely to have
cancer than men.
The risk of NPC is the highest during the ﬁrst year from
the diagnosis of dermatomyositis and remains high for the
next 4 years. In our study, 4 patients with NPC were diag-
nosed within the ﬁrst year from diagnosis of dermatomyositis.
These patients accounted for 80% of the total NPC  cases in
dermatomyositis patients. Twenty percent of them (1 patient)
was diagnosed in the fourth year. While in Singapore, Liu et
al.11 reported 7 NPC with dermatomyositis cases. Five out of 7
patients were diagnosed with malignancy within 1 year from
diagnosis of dermatomyositis (71.4%) while 1 was diagnoseddiagnosis of dermatomyositis (14.3% each).
The onset of NPC is equivalent to the onset of other can-
cers, as reported by Zhang et al.4 They reported that cancer
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10. Stertz G. Polymyositis. Berl Klin Wochenschr 1916;53:489.
11. Liu WC,  Ho M, Koh WP,  et al. An 11-year review of
dermatomyositis in Asian patients. Ann Acad Med Singap
2010;39:843–7.reports of practical oncology and 
all types including nasopharyngeal carcinoma) was detected
n the ﬁrst year after dermatomyositis was diagnosed in
3.5% of patients, 13.9% in the second year and 2.5% in the
hird year. Chow et al.14 and Chen et al.5 reported that the
isk is higher in the ﬁrst year and declined in subsequent
ears. Although the risk of malignancy in dermatomyositis
atients is higher during the ﬁrst 5 years, it remains elevated
ompared to the general population.5 Hence, the search for
alignancy should be continued lifelong for patients with
ermatomyositis.
In our center, biopsies were taken from nasopharynxes
hich appeared suspicious (hyperemia, fullness of fossa of
osenmuller, asymmetry or bulging of nasopharynx) even
hough there were no obvious or exophytic masses and def-
nitely in patients with a mass in the nasopharynx. Sixty
ercent of our biopsies from nasopharynxes without promi-
ent masses showed positive results, while 66% of our biopsies
f nasopharynx masses showed malignancy. One of the
atients was diagnosed with stage T4 of NPC without promi-
ent mass in the nasopharynx. It was reported in Malaysia
hat blind biopsies which had been taken in 10 patients with-
ut obvious masses and one with a mass resulted in 7 out of 11
ound to have NPC.3 Therefore, biopsy should be considered
n all dermatomyositis patients even though there is no lesion
een.
Team approach in managing dermatomyositis can lead to
n early detection of malignancy. In this study, 3 out of 5
atients (60%) were diagnosed with T1, one patient (20%) with
2 and another with T4 stage. Four patients (80%) did not have
ny lymph nodes at diagnosis and one patient had N1 during
he diagnosis of NPC. In Tunisia, nasopharyngeal carcinoma
as  detected at stage T3–4 in 7 cases (87.5%) and stage N2–3
n 5 patients (62.5%).13
From this study, undifferentiated and non-keratinizing
quamous cell carcinoma showed a strong relationship with
ermatomyositis compared to keratinizing well differentiated
quamous cell carcinoma. Histopathological reports of der-
atomyositis patients with NPC showed 2 patients with WHO
ype III (40%) and 3 patients with WHO  type II (60%). None of
he patients had WHO  type I squamous cell carcinoma. These
 types of carcinoma are related to the Epstein–Barr virus15
nd in China it was reported that serum Epstein–Barr viral cap-
id antigen (VCA) IgA antibody was positive in all 59 patients
ith NPC, ranging from 1:20 to 1:320.4
The limitations of this study include a relatively small
ample size and data collection limited to case records,
s it was done retrospectively. The investigation and the
ollow-up of the patients were also not standardized. Serum
pstein–Barr viral capsid IgA antibody was not measured dur-
ng the screening for malignancies in our patients.
We  recommend that all dermatomyositis patients be seen
arly by an otorhinolaryngologist and have regular follow up
ithin the ﬁrst ﬁve years. Serum Epstein–Barr viral capsid
gA antibody screening might be helpful in early detection
f malignancy but rigid nasoendoscopy and biopsy is rec-
mmended in all patients. The screening of dermatomyositis
atients for malignancy could be done using a PET scan when
t is more  affordable and readily available. Future research on
sing PET scan as a diagnostic tool for malignancy in dermato-
yositis may be considered then.therapy 1 9 ( 2 0 1 4 ) 332–336 335
6.  Conclusions
There is a strong relationship between dermatomyositis and
malignancy. NPC is more  common in Asia. Therefore, der-
matomyositis is more  commonly related to nasopharyngeal
carcinoma in Asia. Clinicians should have a high index of sus-
picion for malignancy in all dermatomyositis patients. Rigid
nasoendoscopies and biopsies, serum Epstein–Barr viral cap-
sid IgA antibody and imaging studies have been proven to be
helpful in detecting NPC in dermatomyositis patients. Subse-
quent follow up should be done monthly for the ﬁrst 3 months,
then every 3 months for the ﬁrst two years and every six
months for ﬁve years.
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